GlassScriptPhysician profile
Frances Ferguson
NPI 1174750988
$80,359.77
in general payments reported to CMS, 2019-2025
18 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,427 · 2020: $1,305 · 2021: $10K · 2022: $4,566 · 2023: $18K · 2024: $12K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Travel and Lodging: $13K · Consulting Fee: $9,125 · Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,854.26 |
| Travel and Lodging | $12,588.43 |
| Consulting Fee | $9,125.00 |
| Food and Beverage | $1,479.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $75,619.08 | 2019-2025 | |
| Sanofi Pasteur INC. | $3,436.11 | 2019-2021 | |
| Novo Nordisk INC | $417.81 | 2019-2023 | Ozempic |
| Lilly USA, LLC | $207.25 | 2020-2024 | Jardiance |
| Organogenesis INC. | $121.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.59 | 2023 | |
| Janssen Pharmaceuticals, INC | $80.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $75.36 | 2022-2024 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $55.94 | 2024-2025 | Shingrix, Arexvy |
| Acadia Pharmaceuticals INC | $49.49 | 2019 | |
| Ucb, INC. | $49.22 | 2019 | |
| Boston Scientific Corporation | $30.01 | 2021 | |
| Exact Sciences Corporation | $29.27 | 2023 | Cologuard Collection Kit |
| Depuy Synthes Sales INC. | $27.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.71 | 2022-2023 | Farxiga |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $20.02 | 2020 | |
| Sumitomo Pharma America, INC. | $19.75 | 2023 | Aptiom |
| Esperion Therapeutics, INC. | $15.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.